UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 1)*

	A.P. Pharma, Inc.					
		(Name of Issuer)				
		Common Stock				
		(Title of Class of Securities)				
		00202J203				
		(CUSIP Number)				
		December 31, 2012				
		(Date of Event Which Requires Filing of this Statement)				
Check the app	propriate box to de	esignate the rule pursuant to which this Schedule is filed:				
X	Rule 13d-1(b)					
0	Rule 13d-1(c)					
0	Rule 13d-1(d)					
any subseque The informati	nt amendment cor	age shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for nation which would alter the disclosures provided in a prior cover page. The remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).				
CUSIP No.						
1.	Names of Reporting Persons Tekla Capital Management LLC					
	Tekia Capitai Wi					
7		anagement LLC				
2.	Check the Appro	opriate Box if a Member of a Group (See Instructions)				
2.	Check the Appro	opriate Box if a Member of a Group (See Instructions)				
2.	Check the Appro	opriate Box if a Member of a Group (See Instructions)				
2. 3.	Check the Appro	opriate Box if a Member of a Group (See Instructions)				
	Check the Appro	opriate Box if a Member of a Group (See Instructions)				
3.	Check the Appro	enagement LLC opriate Box if a Member of a Group (See Instructions) o				
3.	Check the Appro	anagement LLC opriate Box if a Member of a Group (See Instructions) o ace of Organization Sole Voting Power				

Shared Dispositive Power

0

8.

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 16,306,333				
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o				
11.	Percent of Class Represented by Amount in Row (9) 5.3%				
12.	Type of Reporting Person (See Instructions) IA				
		2			
CUSIP No.					
1.	Names of Reporting Persons Daniel R. Omstead				
2.	Check the Appropriate Box if a Member of a Group (See Instructions)				
	(a) <u>o</u> (b) <u>o</u>				
3.	SEC Use Only				
4.	Citizenship or Place of Organization Delaware				
	5.	Sole Voting Power			
Number of Shares Beneficially	6.	Shared Voting Power 16,306,333			
Owned by Each Reporting Person With	7.	Sole Dispositive Power 16,306,333			
	8.	Shared Dispositive Power 0			
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 16,306,333				
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o				
11.	Percent of Class Represented by Amount in Row (9) 5.3%				
12.	Type of Reporting Person (See Instructions) IN				
		3			

		A.P. Pharma, Inc.				
	(b)	(b) Address of Issuer's Principal Executive Offices 123 Saginaw Drive, Redwood City, CA 94063				
Item 2.						
	(a)		Person Filing bital Management LLC			
	(b)		of Principal Business Office or, if none, Residence Square, 9 th Floor, Boston, MA 02109			
	(c)	Citizenshi Delaware	ip Corporation			
	(d)	Title of Class of Securities Common Stock				
	(e)	e) CUSIP Number 00202J203				
Item 3.	If thi	f this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:				
	(a)	o Br	oker or dealer registered under section 15 of the Act (15 U.S.C. 780);			
	(b)	o Ba	ank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);			
	(c)	o Ins	surance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);			
	(d)	o Inv	vestment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);			
	(e)	x An	n investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);			
	(f)	o Ar	n employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);			
	(g)	o A	parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);			
	(h)	o A	savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);			
	(i)		church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company et of 1940 (15 U.S.C. 80a-3);			
	(j)	o A	non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);			
	(k)		roup, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii) please specify the type of institution:			
			4			
Item 4. Provide th		vnership ring informa	ation regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.			
	(a	(a) Amount beneficially owned: 16,306,333				
	(b	Percent 5.3%	of class:			
	(0	(c) Number of shares as to which the person has:				
		(i)	Sole power to vote or to direct the vote 0			
		(ii)	Shared power to vote or to direct the vote 16,306,333			
		(iii)	Sole power to dispose or to direct the disposition of 16,306,333			
		(iv)	Shared power to dispose or to direct the disposition of			

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Two persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock of A.P. Pharma, Inc. The interest of H&Q Healthcare Investors, an investment company registered under the Investment Company Act of 1940, in the Common Stock of A.P. Pharma, Inc. amounted to 11,251,340 shares or 3.7% of the total outstanding Common Stock at December 31, 2012. The interest of H&Q Life Sciences Investors, an investment company registered under the Investment Company Act of 1940, in the Common Stock of A.P. Pharma, Inc. amounted to 5,054,933 shares or 1.6% of the total outstanding Common Stock at December 31, 2012.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

See attached Exhibit A.

Item 8. Identification and Classification of Members of the Group

Not applicable.

Item 9. Notice of Dissolution of Group

N/A

5

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 14, 2013
Date
/s/ Laura Woodward
Signature
Laura Woodward, Treasurer
Name/Title

6

Exhibit A

Tekla Capital Management LLC ("TCM"), an investment adviser registered pursuant to Section 203 of the Investment Advisers Act of 1940, is the beneficial owner of 16,306,333 shares (or 5.3%) of the Common Stock of A.P. Pharma, Inc. (the "Company") as a result of acting as investment adviser to H&Q Healthcare Investors ("HQH") and H&Q Life Sciences Investors ("HQL"), each of which is registered as an investment company pursuant to Section 8 of the Investment Company Act of 1940. Each of TCM and Daniel R. Omstead, through his control of TCM, has sole power to dispose of the 16,306,333 shares beneficially owned by HQH and HQL. Neither TCM nor Daniel R. Omstead has the sole power to vote or direct the vote of the shares beneficially owned by HQH and HQL, which power resides in each fund's Board of Trustees. TCM carries out the voting of the shares under written guidelines established by each fund's Board of Trustees.

Joint Filing Agreement

The undersigned persons, on February 14, 2013, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the Common Stock of A.P. Pharma, Inc. on December 31, 2012.

Tekla Capital Management LLC

By /s/ Laura Woodward
Laura Woodward

Daniel R. Omstead

By /s/ Daniel R. Omstead

Daniel R. Omstead